#Lakewood-Amedex #Nu-3 #Peri

Lakewood-Amedex Teams Up with PERI for Nu-3 Clinical Trials

Lakewood-Amedex Biotherapeutics Inc. has announced an exciting new partnership with Professional Education and Research Institute LLC (PERI) to push forward its Phase 2 clinical trial for Nu-3, a promising lead product in the Bisphosphocin® class that functions as a broad-spectrum antimicrobial specifically targeting infected diabetic foot ulcers (iDFU). This collaboration emphasizes Lakewood-Amedex’s commitment to addressing the burgeoning challenge posed by antibiotic-resistant infections, an issue impacting patients globally.

The Significance of Nu-3

Nu-3 is distinguished from traditional treatments by its unique mechanism of action, which has been shown in preliminary in vitro and in vivo testing to effectively eradicate a wide range of bacteria, including resistant strains and biofilms that often complicate infections. The establishment of this Phase 2 trial is crucial as infected diabetic foot ulcers represent a serious complication for many diabetic patients, often resulting in severe morbidity, a heightened risk of amputation, and significant healthcare expenses.

Collaborating with PERI

The choice of PERI as the contract research organization (CRO) for this clinical trial is both strategic and beneficial. Founded by podiatrist Charles Zelen, DPM, FACFAS, PERI holds extensive relational and operational expertise within the fields of podiatric medicine and wound care. This experience is leveraged to enhance patient recruitment and ensure the collection of high-quality trial data—key elements vital for the success of any clinical program.

Dr. Thomas Balzer, Chief Medical Officer of Lakewood-Amedex, expressed enthusiasm about the collaboration,